Clinical Impact and Cost-Effectiveness of a 176-Condition Expanded Carrier Screen

Main|Search|PHGKB




Last Posted: Jul 26, 2018

---

• Clinical Impact and Cost-Effectiveness of a 176-Condition Expanded Carrier Screen
  KA Beachamp et al, BioRXIV, July 2018
• Cost-effective screening of DNMT3A coding sequence identifies somatic mutation in pediatric T-cell acute lymphoblastic leukemia.
  Szarzynska-Zawadzka Bronislawa et al. European journal of haematology 2017 Dec 99(6) 514-519
• The Value of Evidence in the Decision-Making Process for Reimbursement of Pharmacogenetic Dosing of Warfarin.
  Janzic Andrej et al. American journal of cardiovascular drugs : drugs, devices, and other interventions 2017 Oct 17(5) 399-408
• The Price of Precision: Genetic Testing and Drug Costs in America.
  Rich Kelly et al. Genetic testing and molecular biomarkers 2018 Jul 22(7) 403-404
• Buccal swab genomic DNA fragmentation predicts likelihood of successful HLA genotyping by next-generation sequencing.
  Montgomery Maureen C et al. Human immunology 2017 Oct 78(10) 634-641
• Is genome-guided cancer treatment hyped?
  Kaiser Jocelyn et al. Science (New York, N.Y.) 2018 Apr 360(6387) 365
• Are Payers Ready To Address The Financial Challenges Associated With Gene Therapy?
  Health Affairs Blog, June 28, 2018
• Insurance coverage for genomic tests.
  Phillips Kathryn A et al. Science (New York, N.Y.) 2018 Apr 360(6386) 278-279
• 21-Gene recurrence score testing among Medicare beneficiaries with breast cancer in 2010-2013.
  Lynch Julie A et al. Genetics in medicine : official journal of the American College of Medical Genetics 2017 Oct 19(10) 1134-1143
• Hereditary ATTR amyloidosis: burden of illness and diagnostic challenges.
  Gertz Morie A et al. The American journal of managed care 2017 Jun 23(7 Suppl) S107-S112

more